126 related articles for article (PubMed ID: 34398333)
1. The smac mimetic LCL161 targets established pulmonary osteosarcoma metastases in mice.
Harris MA; Shekhar TM; Miles MA; Cerra C; Hawkins CJ
Clin Exp Metastasis; 2021 Oct; 38(5):441-449. PubMed ID: 34398333
[TBL] [Abstract][Full Text] [Related]
2. Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice.
Shekhar TM; Burvenich IJG; Harris MA; Rigopoulos A; Zanker D; Spurling A; Parker BS; Walkley CR; Scott AM; Hawkins CJ
BMC Cancer; 2019 Sep; 19(1):924. PubMed ID: 31521127
[TBL] [Abstract][Full Text] [Related]
3. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Yang C; Wang H; Zhang B; Chen Y; Zhang Y; Sun X; Xiao G; Nan K; Ren H; Qin S
J Exp Clin Cancer Res; 2016 Sep; 35(1):158. PubMed ID: 27737687
[TBL] [Abstract][Full Text] [Related]
4. IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα.
Shekhar TM; Miles MA; Gupte A; Taylor S; Tascone B; Walkley CR; Hawkins CJ
Oncotarget; 2016 Jun; 7(23):33866-86. PubMed ID: 27129149
[TBL] [Abstract][Full Text] [Related]
5. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Effects of a Smac Mimetic with Doxorubicin Against Human Osteosarcoma.
Kamata E; Kawamoto T; Ueha T; Hara H; Fukase N; Minoda M; Morishita M; Takemori T; Fujiwara S; Nishida K; Kuroda R; Kurosaka M; Akisue T
Anticancer Res; 2017 Nov; 37(11):6097-6106. PubMed ID: 29061790
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells.
Chen KF; Lin JP; Shiau CW; Tai WT; Liu CY; Yu HC; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Aug; 84(3):268-77. PubMed ID: 22580047
[TBL] [Abstract][Full Text] [Related]
8. OTUD7B suppresses Smac mimetic-induced lung cancer cell invasion and migration via deubiquitinating TRAF3.
Zhang B; Yang C; Wang R; Wu J; Zhang Y; Liu D; Sun X; Li X; Ren H; Qin S
J Exp Clin Cancer Res; 2020 Nov; 39(1):244. PubMed ID: 33198776
[TBL] [Abstract][Full Text] [Related]
9. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice.
Koshkina NV; Kleinerman ES; Waidrep C; Jia SF; Worth LL; Gilbert BE; Knight V
Clin Cancer Res; 2000 Jul; 6(7):2876-80. PubMed ID: 10914737
[TBL] [Abstract][Full Text] [Related]
10. Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program.
Houghton PJ; Kang MH; Reynolds CP; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock R; Maris JM; Billups CA; Smith MA
Pediatr Blood Cancer; 2012 Apr; 58(4):636-9. PubMed ID: 21681929
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines.
Brands RC; Herbst F; Hartmann S; Seher A; Linz C; Kübler AC; Müller-Richter UDA
Clin Oral Investig; 2016 Dec; 20(9):2325-2332. PubMed ID: 26846923
[TBL] [Abstract][Full Text] [Related]
12. Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases.
Kryeziu K; Moosavi SH; Bergsland CH; Guren MG; Eide PW; Totland MZ; Lassen K; Abildgaard A; Nesbakken A; Sveen A; Lothe RA
J Transl Med; 2021 Sep; 19(1):384. PubMed ID: 34496878
[TBL] [Abstract][Full Text] [Related]
13. The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
Koshkina N; Yang Y; Kleinerman ES
Adv Exp Med Biol; 2020; 1258():177-187. PubMed ID: 32767242
[TBL] [Abstract][Full Text] [Related]
14. Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases.
Lamora A; Mullard M; Amiaud J; Brion R; Heymann D; Redini F; Verrecchia F
Oncotarget; 2015 Jun; 6(16):14413-27. PubMed ID: 26015407
[TBL] [Abstract][Full Text] [Related]
15. LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling.
Afsahi A; Silvestri CM; Moore AE; Graham CF; Bacchiochi K; St-Jean M; Baker CL; Korneluk RG; Beug ST; LaCasse EC; Bramson JL
Front Immunol; 2023; 14():1179827. PubMed ID: 37138866
[TBL] [Abstract][Full Text] [Related]
16. The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis.
Fu Z; Deng B; Liao Y; Shan L; Yin F; Wang Z; Zeng H; Zuo D; Hua Y; Cai Z
BMC Cancer; 2013 Dec; 13():580. PubMed ID: 24314238
[TBL] [Abstract][Full Text] [Related]
17. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.
Gordon N; Kleinerman ES
J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):189-96. PubMed ID: 20528149
[TBL] [Abstract][Full Text] [Related]
18. Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK.
Hu XK; Rao SS; Tan YJ; Yin H; Luo MJ; Wang ZX; Zhou JH; Hong CG; Luo ZW; Du W; Wu B; Yan ZQ; He ZH; Liu ZZ; Cao J; Wang Y; Situ WY; Liu HM; Huang J; Wang YY; Xia K; Qian YX; Zhang Y; Yue T; Liu YW; Zhang HQ; Tang SY; Chen CY; Xie H
Theranostics; 2020; 10(17):7710-7729. PubMed ID: 32685015
[TBL] [Abstract][Full Text] [Related]
19. Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma.
Prasopporn S; Suppramote O; Ponvilawan B; Jamyuang C; Chanthercrob J; Chaiboonchoe A; More-Krong P; Kongsri K; Suntiparpluacha M; Chanwat R; Korphaisarn K; Okada S; Sampattavanich S; Jirawatnotai S
Front Oncol; 2022; 12():1021632. PubMed ID: 36531039
[TBL] [Abstract][Full Text] [Related]
20. Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma.
Ramakrishnan V; Gomez M; Prasad V; Kimlinger T; Painuly U; Mukhopadhyay B; Haug J; Bi L; Rajkumar SV; Kumar S
Oncotarget; 2016 Aug; 7(35):56253-56265. PubMed ID: 27494845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
